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OBJECTIVE—A genome-wide study of adults identiﬁed a vari-
ant of PNPLA3 (rs738409) associated with twofold higher liver
fat. The purpose of this study was to examine the inﬂuence of
PNPLA3 genotype on liver fat and other related metabolic
outcomes in obese Hispanic children and adolescents.
RESEARCH DESIGN AND METHODS—Three hundred and
twenty-seven Hispanics aged 8–18 years were genotyped for
rs738409. One hundred and eighty-eight subjects had measures of
visceral (VAT) and subcutaneous (SAT) adipose tissue volume
and hepatic (HFF) and pancreatic (PFF) fat fraction by magnetic
resonance imaging. One hundred and thirty-nine subjects did not
have HFF measures but had extensive measures of insulin
sensitivity and fasting lipids.
RESULTS—Liver fat in GG subjects was 1.7 and 2.4 times higher
than GC and CC (11.1  0.8% in GG vs. 6.6  0.7% in GC and 4.7 
0.9% in CC; P  0.0001), and this effect was observed even in the
youngest children (8–10 years of age). The variant was not
associated with VAT, SAT, PFF, or insulin sensitivity or other
glucose/insulin indexes. However, Hispanic children carrying the
GG genotype had signiﬁcantly lower HDL cholesterol (40.9 
10.9 in CC vs. 37.0  8.3 in CG vs. 35.7  7.4 in GG; P  0.03) and
a tendency toward lower free fatty acid levels (P  0.06).
CONCLUSIONS—These results provide new evidence that the
effect of the PNPLA3 variant is apparent in Hispanic children and
adolescents, is unique to fat deposition in liver as compared with
other ectopic depots examined, and is associated with lower
HDL cholesterol. Diabetes 59:3127–3130, 2010
T
he prevalence of childhood obesity has risen
dramatically over the past 20 years and is asso-
ciated with increased risk of pre-diabetes, type 2
diabetes, metabolic syndrome, and fatty liver
disease (1). Visceral fat (adipose tissue inside the ab-
dominal cavity) has long been hypothesized to be one of
the major factors linking obesity to increased disease
risks (2) and is certainly an important factor in child-
hood. In addition, ectopic fat deposition through the
spillover of triglycerides into peripheral tissues and
organs, such as muscle and liver, is also an important
factor linking obesity to increased metabolic disease
risk (3).
Previous studies have suggested that hepatic triglycer-
ide accumulation varies between populations and thus
may lead, in part, to different mechanisms by which
metabolic abnormalities arise. For example, a large study
of hepatic fat accumulation (measured by nuclear mag-
netic resonance spectroscopy) in 2,287 adult participants
of the Dallas Heart Study (4) found that fatty liver disease
was highest in Hispanics and lowest in African Americans.
Interestingly, obesity, insulin resistance, or alcohol intake
did not explain this striking ethnic difference. This dispar-
ity has also been reported in the pediatric population
where a study of liver autopsy data from 742 children aged
2–19 years showed that 13% of all subjects had fatty liver
disease (deﬁned as 5% of hepatocytes with macrovesicu-
lar fat) with the prevalence increasing with age and
obesity status (5). Moreover the prevalence of fatty liver
(after adjusting for age and obesity) was highest in His-
panics (11.8%) and lowest in African Americans (1.5%),
reﬂecting the trend observed in adults. These observations
are supported by another recent study of adolescents by
Taksali et al. (6), which did not ﬁnd detectable levels of
hepatic fat in obese African American compared with
whites and Hispanics. Thus, fatty liver disease appears to
be most problematic in Hispanics compared with other
ethnic groups, and this phenomenon is evident by
childhood.
A recent genome-wide association study by Romeo et al.
(7) in adults identiﬁed a novel genetic factor that may
provide a potential explanation for this striking ethnic
difference in liver fat accumulation. A C  G single
nucleotide polymorphism (rs738409) in PNPLA3, which
encodes an amino acid substitution (I148M), was associ-
ated with over twofold higher liver fat content in adults,
with the strongest effect observed in Hispanics in whom
the frequency of the G allele was much higher (48%) than
in other populations (20%). The aim of the present study
was to examine whether the effect of this PNPLA3 variant
is manifested in Hispanic children and adolescents, and
whether its effect was limited to an elevation in liver fat as
opposed to other ectopic fat depots, insulin resistance,
and/or fasting lipid levels.
RESEARCH DESIGN AND METHODS
We pooled subjects from a variety of studies that used a common protocol for
assessment of body fat distribution and metabolic phenotype as described
below. These subjects included 327 Hispanic children and adolescents aged
8–18 years, all of whom were genotyped, with 188 subjects having complete
measures of liver and pancreatic fat fraction as well as abdominal fat
distribution (visceral vs. subcutaneous) as described below. The remaining
139 subjects who were genotyped did not have liver fat measures but had
extensive measures of insulin and glucose from an oral and an intravenous
glucose tolerance test and fasting lipids. Data from some of these subjects has
been previously reported (8–12), but this article is the ﬁrst to examine the
relationship between genotype and these outcomes. Participants and parents
were provided with a full description of the study, and all participants signed
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Weight and height were measured to the nearest 0.1 kg and 0.1 cm,
respectively, using a beam medical scale and wall-mounted stadiometer; BMI
and BMI percentiles were then calculated. Total body fat was measured by
dual-energy X-ray absorptiometry using a Hologic QDR 4500 W (Hologic,
Bedford, MA). Abdominal fat distribution was measured by magnetic reso-
nance imaging (MRI) on a General Electric 1.5-Tesla magnet. Slices were
acquired using a 420-mm ﬁeld of view (FOV) and FOV phase of 75%. Three
abdominal scans were performed consecutively, and total acquisition time
was 24 s per total abdominal scan. Each scan obtained 19 axial images of the
abdomen with a thickness of 10 mm. After image acquisition, subcutaneous
abdominal adipose tissue (SAT) and visceral adipose tissue (VAT) were
segmented using image analysis software (sliceOmatic; TomoVision, Mon-
treal, Canada) at the Image Reading Center (New York, NY). Hepatic and
pancreatic fat fractions were assessed during the same MRI test using a
modiﬁcation of the Dixon three-point technique. Abdominal scans were
acquired contiguously using a breath-hold dual-echo spoiled gradient-recalled
echo sequence with repetition time of 156 ms and echo time of 2.3 ms for
out-of-phase images and 4.78 ms for in-phase (IP) images acquired with ﬂip
angles of 70° and then 20° to provide T1-weighted and intermediate-weighted
images, respectively. A third dual-echo gradient-echo breath-hold gradient-
recalled echo sequence with two IP echoes (4.8 and 9.6 ms) was also
performed to calculate spin-spin relaxation time (T2*) (13). The fat fraction in
the liver was estimated from the signal intensity index obtained from IP and
out-of-phase images. Quantitative corrections for the inﬂuence of T2* decay
on the fat fraction estimates were taken into account by the third duel-echo
sequence where T2* for the liver was estimated on a pixel-by-pixel basis. Since
the fat fraction was estimated from low ﬂip-angle images (20°), the effect of T1
relaxation on the quantiﬁcation was minimized. Once the fat fraction images
were calculated, three consecutive slices with maximum axial coverage of the
liver were selected, avoiding any major blood vessels, to report the average
liver fat fraction.
In all cases, subjects were genotyped for single nucleotide polymorphism
rs738409 in PNPLA3 using the TaqMan system (Applied Biosystems) (14,15)
with an assay available through the Applied Biosystems Assays on Demand
database. Our overall genotype call rate was 97% and we obtained 100%
genotype concordance of four control Centre d’Etude du Polymorphisme
Humain (CEPH) DNA samples that were included on each DNA plate.
Genotype frequencies did not deviate from that expected under Hardy-
Weinberg equilibrium (P  0.92).
Data were analyzed using general linear models in SPSS version 16.0 with
genotype as the main factor, and age, sex, and SAT volume as covariates (the
overall results were similar when using no covariates in the model). Logistic
regression analysis was used to examine prevalence of fatty liver by genotype.
In this analysis, likely fatty liver disease was deﬁned as a liver fat fraction
5.5%, which is based on previous studies in adults using nuclear magnetic
resonance spectroscopy (16), a technique that we have previously validated
against the MRI methodology used in this study (17).
RESULTS
The overall frequency of the PNPLA3 variant was 51.5%,
and the allele distribution was 28% GG/47% CG/24% CC.
The clinical characteristics of the subjects with liver fat
measures are shown in Table 1. As shown in Fig. 1, there
was a highly signiﬁcant effect of genotype on liver fat
fraction with GG carriers having almost double the
amount of liver fat content (P  0.0001). In post hoc
analysis, there was no signiﬁcant difference in liver fat
fraction in CC versus CG carriers. As also shown in Fig. 1,
this relationship remained signiﬁcant even in a younger
sub-group of Hispanic children (aged 8–10 years). Since
liver fat data were skewed, we repeated these analyses
after log transformation, but the results were unchanged.
The data also showed that overall, 38% of Hispanics had
liver fat fraction 5.5%, indicating likely nonalcoholic fatty
liver disease. By comparison, 64% of GG carriers had liver
fat fraction 5.5% (Table 2), leading to an increased odds
ratio of 4.7 for GG relative to GC/CC carriers having liver
fat of 5.5% (95% CI  2.4–9.3; P  0.001). There was no
signiﬁcant effect of genotype on VAT volume, SAT volume,
or pancreatic fat fraction, with or without adjustment for
covariates including age, sex, and overall adiposity.
To determine whether rs738409 was associated with
other metabolic phenotypes, we analyzed data from a
different group of 139 Hispanic subjects (mean age 
10.9  1.7 years; 38.1  6.2% body fat) who had extensive
TABLE 1
Clinical characteristics of subjects with liver fat measurements
n 188
Male/female 59/129
Age (years) 13.6  3.0
BMI 30.3  8.9
SAT volume (L) 9.2  5.9
VAT volume (L) 1.7  1.1
Liver fat fraction (%) 7.1  7.2; median  4.5;
interquartile range  5.8
Pancreatic fat fraction (%) 5.6  3.4
Values are mean  SD except where noted.
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FIG. 1. Liver fat fraction as a function of PNLPA3 genotype in Hispanic
children and teenagers aged 8–18 years and in a subset aged 810
years. Data are least square means  SE of the mean after adjusting for
sex, age, and SAT; overall effect of genotype <0.001.
TABLE 2
Distribution of subjects by genotype and by liver fat fraction
5.5%
Genotype
Liver fat
5.5
Liver fat
5.5
GG (n  53) 36% 64%
CG (n  90) 67% 33%
CC (n  45) 84% 16%
Overall (n  188) 62% 38%
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and intravenous glucose tolerance tests, as well as fasting
lipids, but liver fat measures were not available. There
were no signiﬁcant effects of genotype on any outcome
related to insulin and glucose parameters or lipids, before
or after adjusting for total fat, as measured by dual-energy
X-ray absorptiometry, with the exception of HDL choles-
terol, which was signiﬁcantly lower in GG subjects by
12.7% compared with the CC and CG groups (40.9  10.9
in CC vs. 37.0  8.3 in CG vs. 35.7  7.4 in GG; P  0.03);
in addition there was also a tendency toward lower free
fatty acid levels in GG individuals (0.53  0.21 in CC vs.
0.55  0.11 in CG vs. 0.48  0.1 in GG; P  0.06).
DISCUSSION
Since ﬁrst reported in a genome-wide association study
(7), PNPLA3 has been under investigation to determine its
function and mechanism of action. Importantly, associa-
tion of rs738409 has been replicated in several follow-up
studies with multiple liver-related phenotypes, including
fat content, plasma enzyme levels, and ﬁbrosis (18–21).
For the most part, these studies have all been carried out
in adult populations. However, this study now demon-
strates that the effect of this PNPLA3 variant 1) manifests
early in life in obese Hispanic children; 2) is speciﬁc to the
deposition of triglycerides in liver as opposed to other
ectopic fat depots such as the pancreas and VAT or SAT;
and 3) is also associated with signiﬁcantly lower HDL
cholesterol levels in obese Hispanics.
Recent studies have shown that PNPLA3 is upregulated
during adipocyte differentiation (22) and in response to
positive energy balance, an atherogenic diet, insulin infu-
sion, and nutritional status (23,24). This suggests that
PNPLA3 could have pleiotropic metabolic effects beyond
its role in hepatic triglyceride accumulation. However,
prior studies have shown that the PNPLA3 variant is not
associated with major alterations in glucose homeostasis
or lipoprotein metabolism (7). Based on fasting levels of
insulin and glucose in adults, the G allele was not associ-
ated with insulin resistance in lean individuals but inter-
estingly was associated with increased insulin sensitivity
in obese adults. In the current study we provide evidence
from both an oral and intravenous glucose tolerance test
to show that there is no signiﬁcantly detectable associa-
tion between any fasting or post-challenge (oral and
intravenous) glucose or insulin parameter in Hispanic
children. These data support the idea, as previously pro-
posed (25), that increased liver fat accumulation as a
result of the G allele may be “metabolically benign,” at
least in terms of insulin resistance. Alternatively, the effect
of rs738409 on glucose/insulin homeostasis may not man-
ifest in children (unlike its effect on hepatic fat content)
and thus take longer for it to develop. Lastly, the relatively
small sample size of our study may have also precluded
detecting the association of rs738409 with such metabolic
phenotypes.
Another interesting ﬁnding from our study is the obser-
vation that GG carriers have signiﬁcantly lower HDL
cholesterol levels, which is consistent with a recent study
reporting the same effect in Italian subjects (21). However,
PNPLA3 has not been uniformly associated with lipid
levels in all studies. For example, associations between
PNPLA3 variation and serum lipids have either not been
observed (7,25) or only with apolipoprotein B-containing
lipoproteins (22). Given these ambiguities, as well as those
surrounding glucose/insulin measures, additional studies
will be required to more fully understand the biological
role of PNPLA3 in various processes related to metabolic
homeostasis.
In conclusion, this study demonstrates that the
rs738409 variant of PNPLA3 inﬂuences liver fat deposi-
tion early in life in Hispanic children and adolescents.
These results suggest that more effective therapeutic
strategies for preventing and treating fatty liver need to
be developed, especially for genetically predisposed
pediatric populations.
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